Cipla Limited
Cipla Limited is an India-based pharmaceutical company with a broad international portfolio of branded and generic medicines. Patients may encounter the Cipla name while researching prescription generics, respiratory medicines, urology products, anti-infectives, HIV therapies, or product names associated with sildenafil and tadalafil.
The manufacturer name is only one part of a product search. A Cipla product sold in one country may have a different name, strength, dosage form, labeler, or regulatory status in another. This hub provides company-level context and routes more detailed sildenafil, tadalafil, sexual-health, and broader portfolio questions to the appropriate child pages rather than duplicating them here.
About Cipla
Cipla was founded in 1935. Its current corporate materials describe a global pharmaceutical business with more than 1,500 products across 50-plus dosage forms and a presence in dozens of markets. The company identifies India, South Africa, the United States, and other emerging economies as important markets.
Cipla’s current portfolio spans multiple therapeutic areas. Its corporate materials highlight respiratory medicine, HIV/AIDS, urology, cardiometabolic care, oncology, anti-infectives, central nervous system therapies, and other categories. The company also maintains a substantial generics business in India and a separate North American business.
For a consumer comparing medicines, those company-wide numbers are less important than the exact product in hand. The useful identifiers are the product name, active ingredient, strength, dosage form, manufacturer or distributor, and the country in which the product is being supplied.
Cipla and Generic Medicines
A generic medicine is identified primarily by its active ingredient and approved product information, not simply by the manufacturer’s corporate name. The same ingredient may be sold by several manufacturers, while Cipla itself may market different versions or brands in different countries.
This creates several common search patterns. A user may know only a brand name and want the generic ingredient. Another may know “sildenafil” or “tadalafil” and want to know whether Cipla has a product containing that ingredient. A third may have packaging from another country and want to understand whether the product corresponds to something available locally.
Cipla’s current generics information shows a portfolio spanning more than two dozen therapeutic categories, including a PDE-inhibitor category. Product-level status still needs to be checked in the relevant market because a company’s global portfolio is not a universal availability list.
Sildenafil Products from Cipla
Sildenafil is an active ingredient used in prescription products for erectile dysfunction and, in other formulations and indications, pulmonary arterial hypertension. Product identity matters because strength, indication, labeling, and regulatory status depend on the specific medicine rather than on the ingredient name alone.
Cipla has a documented history with sildenafil products. For example, an official Cipla annual report from 2001 listed Silagra as sildenafil tablets for erectile dysfunction. That historical record confirms the product relationship but does not by itself establish current availability or current approval status in any particular country.
In the United States, current DailyMed labeling identifies sildenafil tablets distributed by Cipla USA under an approved ANDA, with 25 mg, 50 mg, and 100 mg product strengths represented in the listing. That is a product-specific U.S. regulatory fact and should not be generalized to every Cipla sildenafil brand sold elsewhere.
For the site’s more detailed manufacturer-plus-ingredient coverage, see Cipla sildenafil products. That child page is the proper place to evaluate individual names and market details as they are updated.
Tadalafil Products from Cipla
Tadalafil is another PDE5 inhibitor encountered in searches involving erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. These uses should not be collapsed into a single interchangeable product category.
Cipla has U.S. prescription labeling for tadalafil products, and current DailyMed records identify Cipla USA tadalafil under approved ANDAs. One Cipla tadalafil 20 mg product is specifically labeled for pulmonary arterial hypertension. Other U.S. tadalafil listings associated with Cipla include strengths used in the Cialis-reference generic category. The indication on the exact label is what determines how a specific product should be understood.
This distinction is commercially important. A shopper comparing product names should not assume that a 20 mg tadalafil product labeled for pulmonary arterial hypertension is a substitute for an erectile-dysfunction prescription simply because the active ingredient is the same. Product purpose, labeling, strength, and prescription directions must remain attached to the exact product.
For the site’s dedicated tadalafil material, continue to Cipla tadalafil products.
Testosterone and Other Sexual-Health Products
Cipla’s current therapy information confirms activity in urology and includes hypogonadism and sexual dysfunction among the areas it serves. That does not provide a reliable current list of every testosterone brand, formulation, or market.
Cipla has been associated with a range of testosterone products and dosage forms across different markets, but current product status and availability require market-specific verification. For a Cipla testosterone product, the useful starting information is the exact product name, active ingredient, strength, dosage form, and country shown on the packaging.
The existing child reference on Cipla testosterone and other sexual-health products provides additional product-level detail. This parent page does not provide testosterone-replacement prescribing advice or suggest repurposing one product for another indication.
Other Cipla Medicines
Cipla operates far beyond sexual-health medicines. Current corporate information highlights respiratory care as a major long-standing area, together with anti-infectives, HIV/AIDS, urology, cardiometabolic care, oncology, central nervous system products, ophthalmology, and other therapies.
Cipla’s generics business also lists categories such as anti-asthmatic, anti-diabetic, anti-hypertension, anti-infective, antiviral, cardiac, respiratory, pain, gastrointestinal, ophthalmic, and vitamin products. That breadth is useful when a user encounters the Cipla name on a medicine unrelated to sildenafil or tadalafil.
For the site’s broader manufacturer portfolio navigation, see other Cipla medicines.
Regulatory Status and Availability
Regulatory status has to be checked at product level. The U.S. FDA Orange Book identifies specific drug products approved under particular applications. DailyMed publishes current or archived labeling submitted to FDA. Those sources can confirm a particular U.S. product; they do not mean that every Cipla brand containing the same ingredient is FDA-approved.
The same rule applies internationally. A product name used in India, South Africa, the United Kingdom, or another country may have a different registration status from a Cipla USA generic carrying the same active ingredient. Packaging from an overseas market should therefore be checked against that market’s regulator rather than treated as proof of U.S. availability.
Current pharmacy availability is a separate question again. Manufacturer approval and market authorization do not guarantee that a particular pharmacy stocks the product at a particular moment. Paulsen’s Pharmacy does not present this manufacturer hub as a live inventory page.
Research Sources and Manufacturer Information
The Cipla manufacturer reference section uses medication information sources to help explain manufacturer identity, product relationships and market-specific records. Information pages may rely on a combination of official manufacturer information, regulatory databases, national medicines regulators, authoritative medication databases and historical regulatory records where relevant.
The type of source available can differ depending on the product, country, regulatory market and historical period being researched. A product record from one market should not automatically be treated as representing the same status in another market.
About Cipla Product Information
Cipla Limited is a pharmaceutical manufacturer whose products and medication information may appear in different regulatory and market contexts. The Medication Information reference section may discuss manufacturer identity, active ingredients, product names, dosage forms and market-specific records.
These references are intended to help readers understand medication information and product identity. They do not indicate that Paulsen’s Pharmacy works with Cipla, stocks Cipla products, receives products from Cipla or has current availability of any specific Cipla product.
For a broader explanation of how medication information is researched and interpreted, see Medication Information Research Methodology. The main reference library is available through Medication Information.
Questions About a Cipla Product
Before comparing a Cipla medicine or asking about access, collect the details that uniquely identify it:
- the exact product or brand name;
- the active ingredient;
- the strength;
- the dosage form, such as tablet, capsule, inhaler, or liquid;
- the manufacturer, distributor, or labeler shown on the package;
- the country or market for which the product was supplied.
These details make it easier to separate a current approved generic from an older brand name, an imported product, or a similarly named medicine. For help understanding those distinctions across the site, return to Medication Information. For a current pharmacy-specific question, the exact product details can then be used when contacting the pharmacy rather than assuming availability from a reference article.
Reviewed by: Dr. Nancy Ann Curosh